These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 19855267

  • 1. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R.
    Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
    [Abstract] [Full Text] [Related]

  • 2. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE, Pahwa R.
    Mov Disord; 2009 Oct 30; 24(14):2121-7. PubMed ID: 19768728
    [Abstract] [Full Text] [Related]

  • 3. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
    Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, EASE-PD Adjunct Study Investigators.
    Neurology; 2007 Apr 03; 68(14):1108-15. PubMed ID: 17404192
    [Abstract] [Full Text] [Related]

  • 4. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 03; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 5. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort InvestigatorsDepartment of Neurology, University of Rochester, 1351 Mt Hope Ave, Ste 220, Rochester, NY 14620, USA. kevin.biglan@ctcc.rochester.edu.
    Arch Neurol; 2009 May 03; 66(5):563-70. PubMed ID: 19433655
    [Abstract] [Full Text] [Related]

  • 6. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.
    Dusek P, Busková J, Růzicka E, Majerová V, Srp A, Jech R, Roth J, Sonka K.
    Clin Neuropharmacol; 2010 Jul 03; 33(4):186-90. PubMed ID: 20661025
    [Abstract] [Full Text] [Related]

  • 7. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH, Klasser M, Reichmann H.
    Fortschr Neurol Psychiatr; 2008 Oct 03; 76(10):594-9. PubMed ID: 18833504
    [Abstract] [Full Text] [Related]

  • 8. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group.
    Arch Neurol; 2005 Feb 03; 62(2):241-8. PubMed ID: 15710852
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    J Neurol; 2004 Mar 03; 251(3):335-9. PubMed ID: 15015015
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES, Factor SA, Weiner WJ, Sanchez-Ramos JR, Singer C, Shulman L, Brown D, Sheldon C.
    J Neural Transm Suppl; 1995 Mar 03; 45():225-30. PubMed ID: 8748629
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
    Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH, Pramipexole ER Studies Group.
    Neurology; 2011 Aug 23; 77(8):759-66. PubMed ID: 21832218
    [Abstract] [Full Text] [Related]

  • 20. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
    Schrag AE, Brooks DJ, Brunt E, Fuell D, Korczyn A, Poewe W, Quinn NP, Rascol O, Stocchi F.
    Clin Neuropharmacol; 1998 Aug 23; 21(3):169-75. PubMed ID: 9617508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.